Chris Ullsperger’s practice focuses on patent portfolio analysis and patent prosecution for innovative life sciences companies and institutions, as well as for companies seeking to invest in life science technology. Chris has prosecuted and evaluated patents in many biotechnology and life science areas, including RNA interference, nanotechnology, sequencing methods, genetically engineered organisms, personalized medicine, drug-related therapies and crystallography. In addition to his scientific credentials, Chris’ legal background includes several years in the trenches of patent litigation, representing both patentees and accused infringers. Those experiences, as well as his long-standing and close observation of legal trends at the Federal Circuit and Supreme Court level, has sharpened his ability to provide informed, forward-looking, and risk-averse counsel to his clients.
Chris received his Ph.D. in Biochemistry and Molecular Biology from the University of California – Berkeley, where he was a Howard Hughes Predoctoral Fellow and focused his research on topoisomerases and DNA replication, publishing multiple papers of original research in leading peer-reviewed journals including Cell and Science. Chris received his J.D. from the University of California – Hastings College of the Law in 2001 and, prior to joining Fenwick, was an associate at a large IP boutique and an AmLaw 100 firm.